- $23.74bn
- $25.63bn
- $5.46bn
- 94
- 27
- 92
- 82
Annual income statement for Steris, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | R2022 March 31st | R2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,108 | 4,223 | 4,536 | 5,139 | 5,460 |
Cost of Revenue | |||||
Gross Profit | 1,343 | 1,883 | 1,981 | 2,218 | 2,403 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 2,559 | 3,746 | 3,745 | 4,303 | 4,585 |
Operating Profit | 548 | 478 | 791 | 836 | 874 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 518 | 367 | 680 | 703 | 796 |
Provision for Income Taxes | |||||
Net Income After Taxes | 397 | 284 | 556 | 553 | 612 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 397 | 244 | 107 | 378 | 615 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 397 | 244 | 107 | 378 | 615 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 5.18 | 4.91 | 5.85 | 6.2 | 7.09 |
Dividends per Share |